$255 Million is the total value of Affinity Asset Advisors, LLC's 63 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 89.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $21,432,517 | +33.9% | 818,035 | +0.5% | 8.40% | +88.2% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $20,317,500 | +212.6% | 70,000 | -30.0% | 7.97% | +339.3% |
| BMY | New | BRISTOL MYERS SQUIBB COput | $12,591,250 | – | 175,000 | +100.0% | 4.94% | – |
| ESTA | Sell | ESTABLISHMENT LABS HLDGS INC | $12,523,854 | -29.8% | 190,767 | -41.6% | 4.91% | -1.3% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $8,670,864 | -16.0% | 70,997 | -29.0% | 3.40% | +18.0% |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $8,279,200 | – | 80,000 | +100.0% | 3.25% | – |
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $8,250,000 | +459.3% | 75,000 | +200.0% | 3.24% | +685.2% |
| VRNA | Sell | VERONA PHARMA PLCsponsored adr | $8,165,573 | +128.3% | 312,498 | -10.7% | 3.20% | +220.8% |
| Buy | VENTYX BIOSCIENCES INC | $7,890,028 | +32.9% | 240,623 | +41.5% | 3.09% | +86.7% | |
| MORF | Buy | MORPHIC HLDG INC | $7,514,637 | +81.3% | 280,921 | +91.8% | 2.95% | +154.7% |
| Buy | ARCELLX INC | $7,439,630 | +88.6% | 240,143 | +14.3% | 2.92% | +165.0% | |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $7,169,939 | +58.7% | 1,143,531 | -11.4% | 2.81% | +123.0% |
| Buy | ASTRIA THERAPEUTICS INC | $7,035,257 | +94.6% | 472,482 | +18.1% | 2.76% | +173.4% | |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $6,781,100 | – | 215,000 | +100.0% | 2.66% | – |
| NARI | Sell | INARI MED INC | $5,720,400 | -34.4% | 90,000 | -25.0% | 2.24% | -7.8% |
| MRNA | New | MODERNA INCput | $5,388,600 | – | 30,000 | +100.0% | 2.11% | – |
| AMGN | New | AMGEN INCput | $5,252,800 | – | 20,000 | +100.0% | 2.06% | – |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $5,121,000 | – | 45,000 | +100.0% | 2.01% | – |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $5,051,311 | +18.2% | 258,115 | -3.6% | 1.98% | +66.1% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $4,902,700 | +118.0% | 110,000 | +37.5% | 1.92% | +206.2% |
| BLU | Buy | BELLUS HEALTH INC NEW | $4,715,633 | -5.7% | 573,678 | +21.1% | 1.85% | +32.4% |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $4,068,000 | -50.5% | 60,000 | -60.0% | 1.60% | -30.5% |
| CYTK | Buy | CYTOKINETICS INC | $4,013,878 | +27.5% | 87,601 | +34.8% | 1.57% | +79.1% |
| BRIDGEBIO PHARMA INCnote 2.250% 2/0 | $3,895,290 | -12.2% | 10,000,000 | 0.0% | 1.53% | +23.4% | ||
| BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $3,410,048 | -24.1% | 7,500,000 | 0.0% | 1.34% | +6.6% | ||
| KURA | Sell | KURA ONCOLOGY INC | $3,335,150 | -63.9% | 268,747 | -60.2% | 1.31% | -49.2% |
| VKTX | Buy | VIKING THERAPEUTICS INC | $3,290,000 | +383.8% | 350,000 | +40.0% | 1.29% | +578.9% |
| LNTH | Sell | LANTHEUS HLDGS INC | $3,089,705 | -66.2% | 60,630 | -53.4% | 1.21% | -52.5% |
| PCVX | New | VAXCYTE INC | $2,877,000 | – | 60,000 | +100.0% | 1.13% | – |
| VRNA | New | VERONA PHARMA PLCcall | $2,743,650 | – | 105,000 | +100.0% | 1.08% | – |
| GERN | Buy | GERON CORPput | $2,556,730 | +68.1% | 1,056,500 | +62.5% | 1.00% | +136.0% |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,545,000 | – | 100,000 | +100.0% | 1.00% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $2,396,250 | – | 375,000 | +100.0% | 0.94% | – |
| VKTX | New | VIKING THERAPEUTICS INCcall | $2,350,000 | – | 250,000 | +100.0% | 0.92% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $2,248,298 | – | 661,264 | +100.0% | 0.88% | – |
| COGT | Buy | COGENT BIOSCIENCES INC | $2,231,820 | -2.9% | 193,064 | +25.3% | 0.88% | +36.3% |
| PNT | Sell | POINT BIOPHARMA GLOBAL INC | $2,210,459 | -61.7% | 303,218 | -59.4% | 0.87% | -46.2% |
| NVAX | New | NOVAVAX INCput | $2,056,000 | – | 200,000 | +100.0% | 0.81% | – |
| GERN | Buy | GERON CORPcall | $2,025,540 | +38.3% | 837,000 | +33.7% | 0.79% | +94.1% |
| XENE | New | XENON PHARMACEUTICALS INC | $1,971,500 | – | 50,000 | +100.0% | 0.77% | – |
| ARGX | New | ARGENX SEsponsored adr | $1,894,150 | – | 5,000 | +100.0% | 0.74% | – |
| NVCR | New | NOVOCURE LTDcall | $1,833,750 | – | 25,000 | +100.0% | 0.72% | – |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $1,821,999 | +130.1% | 247,891 | +125.4% | 0.72% | +223.5% |
| VINC | VINCERX PHARMA INC | $1,522,626 | -26.1% | 1,492,771 | 0.0% | 0.60% | +3.8% | |
| PRECIGEN INCnote 3.500% 7/0 | $1,487,981 | +2.3% | 1,500,000 | 0.0% | 0.58% | +43.8% | ||
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $1,427,017 | +46.4% | 460,328 | +89.8% | 0.56% | +105.9% |
| New | ESPERION THERAPEUTICS INC NEnote 4.000%11/1 | $1,363,928 | – | 2,500,000 | +100.0% | 0.54% | – | |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $1,272,854 | -9.0% | 188,292 | +95.5% | 0.50% | +27.9% |
| BCAB | New | BIOATLA INC | $1,237,500 | – | 150,000 | +100.0% | 0.48% | – |
| DYN | New | DYNE THERAPEUTICS INC | $1,068,250 | – | 92,170 | +100.0% | 0.42% | – |
| Buy | LIANBIOsponsored ads | $1,066,000 | -2.6% | 650,000 | +18.2% | 0.42% | +36.6% | |
| NRIX | New | NURIX THERAPEUTICS INC | $878,400 | – | 80,000 | +100.0% | 0.34% | – |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $780,000 | – | 40,000 | +100.0% | 0.31% | – |
| FHTX | New | FOGHORN THERAPEUTICS INC | $701,743 | – | 109,991 | +100.0% | 0.28% | – |
| SGEN | New | SEAGEN INC | $642,550 | – | 5,000 | +100.0% | 0.25% | – |
| CONTEXT THERAPEUTICS INC | $583,653 | -40.5% | 883,654 | 0.0% | 0.23% | -16.4% | ||
| INZY | New | INOZYME PHARMA INC | $525,000 | – | 500,000 | +100.0% | 0.21% | – |
| NUVB | New | NUVATION BIO INC | $480,000 | – | 250,000 | +100.0% | 0.19% | – |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $469,882 | -7.3% | 187,204 | 0.0% | 0.18% | +29.6% | |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $396,000 | – | 100,000 | +100.0% | 0.16% | – |
| New | SCILEX HOLDING CO*w exp 11/10/202 | $3,419 | – | 18,099 | +100.0% | 0.00% | – | |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $2,933 | -2.2% | 33,333 | 0.0% | 0.00% | 0.0% | |
| New | SCILEX HOLDING CO | $1,847 | – | 463 | +100.0% | 0.00% | – | |
| Exit | RENOVACOR INC*w exp 99/99/999 | $0 | – | -75,000 | -100.0% | -0.00% | – | |
| VCKAW | Exit | VICKERS VANTAGE CORP I*w exp 09/15/202 | $0 | – | -100,000 | -100.0% | -0.01% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -81,982 | -100.0% | -0.08% | – | |
| Exit | RENOVACOR INC | $0 | – | -199,490 | -100.0% | -0.14% | – | |
| KURA | Exit | KURA ONCOLOGY INCput | $0 | – | -37,100 | -100.0% | -0.14% | – |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -30,000 | -100.0% | -0.15% | – |
| VERV | Exit | VERVE THERAPEUTICS INCcall | $0 | – | -20,000 | -100.0% | -0.19% | – |
| NAUT | Exit | NAUTILUS BIOTECHNOLOGY INC | $0 | – | -372,476 | -100.0% | -0.22% | – |
| FXB | Exit | INVESCO CURRENCYSHARES BRITput | $0 | – | -10,000 | -100.0% | -0.30% | – |
| MIST | Exit | MILESTONE PHARMACEUTICALS INcall | $0 | – | -137,200 | -100.0% | -0.35% | – |
| VRNA | Exit | VERONA PHARMA PLCput | $0 | – | -165,100 | -100.0% | -0.47% | – |
| FXE | Exit | INVESCO CURRENCYSHARES EUROput | $0 | – | -20,000 | -100.0% | -0.50% | – |
| LNTH | Exit | LANTHEUS HLDGS INCput | $0 | – | -30,000 | -100.0% | -0.59% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -136,434 | -100.0% | -0.60% | – |
| Exit | GSK PLCsponsored adr | $0 | – | -75,000 | -100.0% | -0.62% | – | |
| Exit | GSK PLCput | $0 | – | -110,000 | -100.0% | -0.90% | – | |
| Exit | ARYA SCIENCES ACQUISITN CORP | $0 | – | -352,500 | -100.0% | -0.97% | – | |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -170,000 | -100.0% | -1.03% | – |
| PEN | Exit | PENUMBRA INCcall | $0 | – | -25,000 | -100.0% | -1.32% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INCput | $0 | – | -75,000 | -100.0% | -1.36% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -175,000 | -100.0% | -1.39% | – |
| AZN | Exit | ASTRAZENECA PLCput | $0 | – | -100,000 | -100.0% | -1.53% | – |
| Exit | NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $0 | – | -10,000,000 | -100.0% | -2.38% | – | |
| SNY | Exit | SANOFIput | $0 | – | -250,000 | -100.0% | -2.65% | – |
| Exit | TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $0 | – | -11,000,000 | -100.0% | -3.11% | – | |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -300,000 | -100.0% | -3.18% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -70,000 | -100.0% | -3.22% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -190,000 | -100.0% | -3.61% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -250,000 | -100.0% | -24.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.